HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
2.030
-0.030 (-1.46%)
Dec 4, 2025, 4:00 PM EST - Market closed
HCW Biologics Revenue
HCW Biologics had revenue of $15.61K in the quarter ending September 30, 2025, a decrease of -96.34%. This brings the company's revenue in the last twelve months to $422.03K, down -87.93% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$422.03K
Revenue Growth
-87.93%
P/S Ratio
7.30
Revenue / Employee
$11,723
Employees
36
Market Cap
8.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 4.10M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HCWB News
- 17 days ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire
- 20 days ago - HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 weeks ago - HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 7 weeks ago - HCW Biologics to Participate in the 2025 Maxim Growth Summit - GlobeNewsWire
- 2 months ago - HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - GlobeNewsWire
- 2 months ago - HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewsWire
- 2 months ago - HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - GlobeNewsWire
- 3 months ago - HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform - Benzinga